Skip to content
  • Home
  • About
    • Overview
    • Team Background
    • Public Healthcare
  • Team
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Senior Advisors
  • Programs
    • Overview
    • Pipeline
    • Strategic Partners
    • Drug Candidates
      • CO-sTiRNA™
      • MRI-1867
      • Additional R&D Programs
    • Scientific Publications
  • Media
  • News and Events
    • Press Releases
    • News
    • Events
    • Presentations
  • Investors
    • Company Information
    • News and Events
    • Presentations
    • SEC Filings
    • Corporate Governance
    • Stock Data
    • Research Coverage
  • Contact
Menu
  • Home
  • About
    • Overview
    • Team Background
    • Public Healthcare
  • Team
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Senior Advisors
  • Programs
    • Overview
    • Pipeline
    • Strategic Partners
    • Drug Candidates
      • CO-sTiRNA™
      • MRI-1867
      • Additional R&D Programs
    • Scientific Publications
  • Media
  • News and Events
    • Press Releases
    • News
    • Events
    • Presentations
  • Investors
    • Company Information
    • News and Events
    • Presentations
    • SEC Filings
    • Corporate Governance
    • Stock Data
    • Research Coverage
  • Contact

Scopus BioPharma (Nasdaq: SCPS) is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions.

 

Our lead development program, CO-sTiRNA, is a novel, targeted immuno-oncology gene transfer for the treatment of multiple cancers. Our second lead development program, MRI-1867, is a peripherally-restricted, dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS.

Press Releases

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

November 10, 2022

Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value

October 18, 2022

Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

May 5, 2022

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit

March 22, 2022

Pipeline

Program
Drug Candidate
Pre-Clinical Testing
IND-Enabling Studies
Phase 1
Gene Therapy
CO-sTiRNA
B-cell Non-Hodgkin's Lymphoma
CO-sTiRNA
+
Checkpoint Inhibitors
and/or
CAR-Ts
B-cell Non-Hodgkin's Lymphoma
Cutaneous T-cell Lymphoma
Other Solid Tumors
CB1R Inverse Agonists
MRI-1867
Systemic Sclerosis
SCPS Chart by TradingView
  • Home
  • About
    • Overview
    • Team Background
    • Public Healthcare
  • Team
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Senior Advisors
  • Programs
    • Overview
    • Pipeline
    • Strategic Partners
    • Drug Candidates
      • CO-sTiRNA™
      • MRI-1867
      • Additional R&D Programs
    • Scientific Publications
  • Media
  • News and Events
    • Press Releases
    • News
    • Events
    • Presentations
  • Investors
    • Company Information
    • News and Events
    • Presentations
    • SEC Filings
    • Corporate Governance
    • Stock Data
    • Research Coverage
  • Contact
Menu
  • Home
  • About
    • Overview
    • Team Background
    • Public Healthcare
  • Team
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Senior Advisors
  • Programs
    • Overview
    • Pipeline
    • Strategic Partners
    • Drug Candidates
      • CO-sTiRNA™
      • MRI-1867
      • Additional R&D Programs
    • Scientific Publications
  • Media
  • News and Events
    • Press Releases
    • News
    • Events
    • Presentations
  • Investors
    • Company Information
    • News and Events
    • Presentations
    • SEC Filings
    • Corporate Governance
    • Stock Data
    • Research Coverage
  • Contact
  • Contact
Menu
  • Contact

About

  • Overview
  • Team Background
  • Public Healthcare
Menu
  • Overview
  • Team Background
  • Public Healthcare

Team

  • Leadership
  • Board of Directors
  • Scientific Advisory Board
  • Senior Advisors
Menu
  • Leadership
  • Board of Directors
  • Scientific Advisory Board
  • Senior Advisors

Programs

  • Overview
  • Pipeline
  • Strategic Partners
  • Drug Candidates
  • CO-sTiRNA™
  • MRI-1867
  • Additional R&D Programs
  • Scientific Publications
Menu
  • Overview
  • Pipeline
  • Strategic Partners
  • Drug Candidates
  • CO-sTiRNA™
  • MRI-1867
  • Additional R&D Programs
  • Scientific Publications

Media

  • Media
Menu
  • Media

News and Events

  • Press Releases
  • News
  • Events
  • Presentations
Menu
  • Press Releases
  • News
  • Events
  • Presentations

Investors

  • Company Information
  • News and Events
  • Presentations
  • SEC Filings
  • Corporate Governance
  • Stock Data
  • Research Coverage
Menu
  • Company Information
  • News and Events
  • Presentations
  • SEC Filings
  • Corporate Governance
  • Stock Data
  • Research Coverage
  • Contact
Menu
  • Contact

© 2023 Scopus BioPharma. All rights reserved | Privacy Policy | Cookies Policy